LLY•benzinga•
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Summary
Novo Nordisk's REDEFINE 1 trial shows CagriSema delivers significant weight loss and a favorable safety profile in obesity treatment.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 20, 2024 by benzinga